The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column reviews various issues related to the preparation, dispensing, and administration of cancer chemotherapy, both commercially available and investigational.
Get full access to this article
View all access options for this article.
References
1.
RussellC.A., GreenS.J., O'SullivanJ., HynesH.E., BuddG.T., CongdonJ.E.Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial. J Clin Oncol.1997; 15(7): 2494–501.
2.
SantenR.J., WorgulT.J., SamojlikE., InterranteA., BoucherA.E., BoucherA.E.A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. N Engl J Med.1981; 305(10): 545–51.
3.
DragoJ.R., SantenR.J., LiptonA., WorgulT.J., HarveyH.A., BoucherA.Clinical effect of aminoglutethimide, medical adrenalectomy, in treatment of 43 patients with advanced prostatic cancer. Cancer.1984; 53(7): 1447–50.
4.
CarellaM.J., DimitrovN.V., GossainV.V., SrivastavaL., RovnerD.R.Adrenal effects of low-dose aminoglutethimide when used alone in postmenopausal women with advanced breast cancer. Metabolism.1994; 43(6): 723–27.
5.
Robustelli della CunaG., PannutiF., MartoniA., CamaggiC.M., StrocchiE., Da PradaG.A., TannebergerS.Aminoglutethimide in advanced breast cancer: prospective, randomized comparison of two dose levels. Italian Cooperative Group. Anticancer Res.1993; 13(6B): 2367–71.
6.
BrueraE., ErnstS., HagenN., SpachynskiK., BelzileM., HansonJ.Effectiveness of megestrol acetate in patients with advanced cancer: A randomized, double-blind, crossover study. Cancer Prev Control.1998; 2(2): 74–8.
7.
BuzdarA.U., JonatW., HowellA., JonesS.E., BlomqvistC.P., VogelC.L.Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer.1998; 83(6): 1142–52.
8.
VadellC., SeguiM.A., Gimenez-ArnauJ.M., MoralesS., CireraL., BestitI.Anti cachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia. Am J Clin Oncol.1998; 21(4): 347–51.
9.
FietkauR., RieplM., KettnerH., HinkeA., SauerR.Supportive use of megestrol acetate in patients with head and neck cancer during radio(chemo)therapy. Eur J Cancer.1997; 33(1): 75–9.
10.
BuzdarA., JonatW., HowellA., JonesS.E., BlomqvistC., VogelC.L.Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol.1996; 14(7): 2000–11.
11.
VeenhofC.H., van der BurgM.E., NooyM., AaldersJ.G., PecorelliS., OliveiraC.F.Phase II study of high-dose megestrol acetate in patients with advanced ovarian carcinoma. Eur J Cancer.1994; 30A(5): 697–98.
12.
DixonA.R., JacksonL., ChanS., HaybittleJ., BlameyR.W.A randomised trial of second- line hormone vs single agent chemotherapy in tamoxifen resistant advanced breast cancer. Br J Cancer.1992; 66(2): 402–4.
